nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2E1—liver cancer	0.4	0.503	CbGaD
Dexmedetomidine—CYP1A1—liver cancer	0.394	0.497	CbGaD
Dexmedetomidine—Hypoalbuminaemia—Sorafenib—liver cancer	0.00783	0.0617	CcSEcCtD
Dexmedetomidine—Infarction—Sorafenib—liver cancer	0.00616	0.0486	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Sorafenib—liver cancer	0.00294	0.0232	CcSEcCtD
Dexmedetomidine—Haemoglobin decreased—Sorafenib—liver cancer	0.00248	0.0196	CcSEcCtD
Dexmedetomidine—Pleural effusion—Sorafenib—liver cancer	0.00223	0.0176	CcSEcCtD
Dexmedetomidine—Myocardial ischaemia—Sorafenib—liver cancer	0.00213	0.0168	CcSEcCtD
Dexmedetomidine—Septic shock—Epirubicin—liver cancer	0.00209	0.0165	CcSEcCtD
Dexmedetomidine—Septic shock—Doxorubicin—liver cancer	0.00193	0.0153	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Sorafenib—liver cancer	0.00187	0.0147	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Epirubicin—liver cancer	0.00157	0.0124	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Doxorubicin—liver cancer	0.00145	0.0114	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Sorafenib—liver cancer	0.00142	0.0112	CcSEcCtD
Dexmedetomidine—Renal failure acute—Sorafenib—liver cancer	0.00134	0.0106	CcSEcCtD
Dexmedetomidine—Pneumothorax—Epirubicin—liver cancer	0.00127	0.01	CcSEcCtD
Dexmedetomidine—Hypernatraemia—Epirubicin—liver cancer	0.0012	0.00947	CcSEcCtD
Dexmedetomidine—Pneumothorax—Doxorubicin—liver cancer	0.00117	0.00926	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Sorafenib—liver cancer	0.00113	0.0089	CcSEcCtD
Dexmedetomidine—Hypothermia—Epirubicin—liver cancer	0.00113	0.00889	CcSEcCtD
Dexmedetomidine—Body temperature decreased—Epirubicin—liver cancer	0.00113	0.00889	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00112	0.00881	CcSEcCtD
Dexmedetomidine—Hypernatraemia—Doxorubicin—liver cancer	0.00111	0.00877	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00109	0.00863	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Epirubicin—liver cancer	0.00109	0.00857	CcSEcCtD
Dexmedetomidine—Generalised oedema—Epirubicin—liver cancer	0.00106	0.00837	CcSEcCtD
Dexmedetomidine—Body temperature decreased—Doxorubicin—liver cancer	0.00104	0.00822	CcSEcCtD
Dexmedetomidine—Hypothermia—Doxorubicin—liver cancer	0.00104	0.00822	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Doxorubicin—liver cancer	0.00101	0.00793	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Epirubicin—liver cancer	0.000994	0.00784	CcSEcCtD
Dexmedetomidine—Generalised oedema—Doxorubicin—liver cancer	0.000982	0.00775	CcSEcCtD
Dexmedetomidine—Pneumonia—Sorafenib—liver cancer	0.000961	0.00758	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Sorafenib—liver cancer	0.000942	0.00743	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Sorafenib—liver cancer	0.000937	0.00739	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Sorafenib—liver cancer	0.000937	0.00739	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Doxorubicin—liver cancer	0.00092	0.00725	CcSEcCtD
Dexmedetomidine—Neuralgia—Epirubicin—liver cancer	0.000909	0.00717	CcSEcCtD
Dexmedetomidine—Haemoglobin—Sorafenib—liver cancer	0.000862	0.0068	CcSEcCtD
Dexmedetomidine—Haemorrhage—Sorafenib—liver cancer	0.000858	0.00677	CcSEcCtD
Dexmedetomidine—Ventricular arrhythmia—Epirubicin—liver cancer	0.000853	0.00673	CcSEcCtD
Dexmedetomidine—Neuritis—Epirubicin—liver cancer	0.000846	0.00667	CcSEcCtD
Dexmedetomidine—Neuralgia—Doxorubicin—liver cancer	0.000841	0.00663	CcSEcCtD
Dexmedetomidine—Pleural effusion—Epirubicin—liver cancer	0.000825	0.0065	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Sorafenib—liver cancer	0.000796	0.00628	CcSEcCtD
Dexmedetomidine—Ventricular arrhythmia—Doxorubicin—liver cancer	0.000789	0.00623	CcSEcCtD
Dexmedetomidine—Neuritis—Doxorubicin—liver cancer	0.000783	0.00617	CcSEcCtD
Dexmedetomidine—Angiopathy—Sorafenib—liver cancer	0.000779	0.00614	CcSEcCtD
Dexmedetomidine—Rigors—Epirubicin—liver cancer	0.000774	0.0061	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Sorafenib—liver cancer	0.000773	0.0061	CcSEcCtD
Dexmedetomidine—Arrhythmia—Sorafenib—liver cancer	0.000767	0.00605	CcSEcCtD
Dexmedetomidine—Pleural effusion—Doxorubicin—liver cancer	0.000763	0.00602	CcSEcCtD
Dexmedetomidine—Mental disorder—Sorafenib—liver cancer	0.000752	0.00593	CcSEcCtD
Dexmedetomidine—Malnutrition—Sorafenib—liver cancer	0.000747	0.00589	CcSEcCtD
Dexmedetomidine—Delirium—Epirubicin—liver cancer	0.000734	0.00579	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Epirubicin—liver cancer	0.000719	0.00567	CcSEcCtD
Dexmedetomidine—Rigors—Doxorubicin—liver cancer	0.000716	0.00564	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Epirubicin—liver cancer	0.000694	0.00548	CcSEcCtD
Dexmedetomidine—Anaemia—Sorafenib—liver cancer	0.00069	0.00545	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Epirubicin—liver cancer	0.00069	0.00544	CcSEcCtD
Dexmedetomidine—Oliguria—Epirubicin—liver cancer	0.000685	0.0054	CcSEcCtD
Dexmedetomidine—Delirium—Doxorubicin—liver cancer	0.000679	0.00536	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Doxorubicin—liver cancer	0.000665	0.00525	CcSEcCtD
Dexmedetomidine—Atrioventricular block—Epirubicin—liver cancer	0.000651	0.00513	CcSEcCtD
Dexmedetomidine—Hypertension—Sorafenib—liver cancer	0.000645	0.00509	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000643	0.00507	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Doxorubicin—liver cancer	0.000638	0.00503	CcSEcCtD
Dexmedetomidine—Oliguria—Doxorubicin—liver cancer	0.000634	0.005	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000632	0.00498	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Epirubicin—liver cancer	0.000632	0.00498	CcSEcCtD
Dexmedetomidine—Dry mouth—Sorafenib—liver cancer	0.000622	0.00491	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Epirubicin—liver cancer	0.00062	0.00489	CcSEcCtD
Dexmedetomidine—Infection—Sorafenib—liver cancer	0.000606	0.00478	CcSEcCtD
Dexmedetomidine—Atrioventricular block—Doxorubicin—liver cancer	0.000602	0.00475	CcSEcCtD
Dexmedetomidine—Fluid retention—Epirubicin—liver cancer	0.0006	0.00473	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Sorafenib—liver cancer	0.000597	0.00471	CcSEcCtD
Dexmedetomidine—Blood urea increased—Epirubicin—liver cancer	0.000596	0.0047	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000584	0.00461	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Doxorubicin—liver cancer	0.000584	0.00461	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Doxorubicin—liver cancer	0.000574	0.00453	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Epirubicin—liver cancer	0.000562	0.00443	CcSEcCtD
Dexmedetomidine—Fluid retention—Doxorubicin—liver cancer	0.000555	0.00438	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—liver cancer	0.000552	0.00435	CcSEcCtD
Dexmedetomidine—Abnormal vision—Epirubicin—liver cancer	0.000551	0.00434	CcSEcCtD
Dexmedetomidine—Sepsis—Epirubicin—liver cancer	0.000548	0.00432	CcSEcCtD
Dexmedetomidine—Dyspnoea—Sorafenib—liver cancer	0.000544	0.00429	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000527	0.00416	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Sorafenib—liver cancer	0.000526	0.00415	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Epirubicin—liver cancer	0.000525	0.00414	CcSEcCtD
Dexmedetomidine—Constipation—Sorafenib—liver cancer	0.000521	0.00411	CcSEcCtD
Dexmedetomidine—Pain—Sorafenib—liver cancer	0.000521	0.00411	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—liver cancer	0.00052	0.0041	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—liver cancer	0.00051	0.00402	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—liver cancer	0.000507	0.004	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Sorafenib—liver cancer	0.000499	0.00393	CcSEcCtD
Dexmedetomidine—Renal failure acute—Epirubicin—liver cancer	0.000497	0.00392	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000488	0.00385	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—liver cancer	0.000485	0.00383	CcSEcCtD
Dexmedetomidine—Abdominal pain—Sorafenib—liver cancer	0.000482	0.0038	CcSEcCtD
Dexmedetomidine—Body temperature increased—Sorafenib—liver cancer	0.000482	0.0038	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Epirubicin—liver cancer	0.00047	0.0037	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—liver cancer	0.000459	0.00362	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Epirubicin—liver cancer	0.000436	0.00344	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—liver cancer	0.000435	0.00343	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Epirubicin—liver cancer	0.000417	0.00329	CcSEcCtD
Dexmedetomidine—Diarrhoea—Sorafenib—liver cancer	0.000417	0.00329	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000413	0.00326	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000404	0.00319	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—liver cancer	0.000403	0.00318	CcSEcCtD
Dexmedetomidine—Dizziness—Sorafenib—liver cancer	0.000403	0.00318	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—liver cancer	0.000399	0.00315	CcSEcCtD
Dexmedetomidine—Vomiting—Sorafenib—liver cancer	0.000388	0.00306	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—liver cancer	0.000386	0.00304	CcSEcCtD
Dexmedetomidine—Rash—Sorafenib—liver cancer	0.000384	0.00303	CcSEcCtD
Dexmedetomidine—Dermatitis—Sorafenib—liver cancer	0.000384	0.00303	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000382	0.00301	CcSEcCtD
Dexmedetomidine—Headache—Sorafenib—liver cancer	0.000382	0.00301	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000374	0.00295	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—liver cancer	0.000369	0.00291	CcSEcCtD
Dexmedetomidine—Nausea—Sorafenib—liver cancer	0.000362	0.00286	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—liver cancer	0.000357	0.00282	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—liver cancer	0.000355	0.0028	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—liver cancer	0.000346	0.00273	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—liver cancer	0.000343	0.00271	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—liver cancer	0.000331	0.00261	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—liver cancer	0.000329	0.00259	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—liver cancer	0.000323	0.00255	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—liver cancer	0.00032	0.00253	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—liver cancer	0.000319	0.00251	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—liver cancer	0.000318	0.00251	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—liver cancer	0.000317	0.0025	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—liver cancer	0.000312	0.00246	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—liver cancer	0.000306	0.00241	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—liver cancer	0.000299	0.00236	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—liver cancer	0.000295	0.00233	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—liver cancer	0.000294	0.00232	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—liver cancer	0.000293	0.00231	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—liver cancer	0.000289	0.00228	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—liver cancer	0.000288	0.00227	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—liver cancer	0.000286	0.00225	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—liver cancer	0.000285	0.00224	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—liver cancer	0.000283	0.00223	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—liver cancer	0.000283	0.00223	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—liver cancer	0.000278	0.00219	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—liver cancer	0.000276	0.00218	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—liver cancer	0.000272	0.00215	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—liver cancer	0.000266	0.0021	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—liver cancer	0.000264	0.00209	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—liver cancer	0.000263	0.00208	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—liver cancer	0.000262	0.00207	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—liver cancer	0.000257	0.00203	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—liver cancer	0.000255	0.00201	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—liver cancer	0.000255	0.00201	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—liver cancer	0.000254	0.002	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—liver cancer	0.000239	0.00189	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—liver cancer	0.000238	0.00188	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—liver cancer	0.000236	0.00186	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—liver cancer	0.000235	0.00185	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—liver cancer	0.000234	0.00185	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—liver cancer	0.00023	0.00181	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—liver cancer	0.000227	0.00179	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—liver cancer	0.000224	0.00177	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—liver cancer	0.000221	0.00175	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—liver cancer	0.000221	0.00174	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—liver cancer	0.000221	0.00174	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—liver cancer	0.00022	0.00173	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—liver cancer	0.000218	0.00172	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—liver cancer	0.000217	0.00171	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—liver cancer	0.000213	0.00168	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—liver cancer	0.000211	0.00166	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—liver cancer	0.00021	0.00166	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—liver cancer	0.000207	0.00163	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—liver cancer	0.000204	0.00161	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—liver cancer	0.000203	0.0016	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—liver cancer	0.000202	0.00159	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—liver cancer	0.000201	0.00158	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—liver cancer	0.0002	0.00158	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—liver cancer	0.000195	0.00154	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000195	0.00153	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—liver cancer	0.000193	0.00152	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—liver cancer	0.000193	0.00152	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—liver cancer	0.000186	0.00147	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—liver cancer	0.000186	0.00146	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—liver cancer	0.000185	0.00146	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—liver cancer	0.000184	0.00145	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00018	0.00142	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—liver cancer	0.000178	0.00141	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—liver cancer	0.000178	0.00141	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—liver cancer	0.000178	0.0014	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—liver cancer	0.000178	0.0014	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—liver cancer	0.000172	0.00135	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—liver cancer	0.00017	0.00134	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—liver cancer	0.000165	0.0013	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—liver cancer	0.000165	0.0013	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—liver cancer	0.000154	0.00122	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—liver cancer	0.000149	0.00118	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—liver cancer	0.000143	0.00113	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—liver cancer	0.000143	0.00113	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—liver cancer	0.000142	0.00112	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—liver cancer	0.000142	0.00112	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—liver cancer	0.000141	0.00111	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—liver cancer	0.000138	0.00109	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—liver cancer	0.000134	0.00106	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—liver cancer	0.000133	0.00105	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—liver cancer	0.000131	0.00104	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—liver cancer	0.000131	0.00104	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—liver cancer	0.000131	0.00103	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—liver cancer	0.000124	0.000977	CcSEcCtD
Dexmedetomidine—CYP2E1—Metabolism—MTHFR—liver cancer	1.08e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK14—liver cancer	1.08e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.08e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ESR1—liver cancer	1.08e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CB—liver cancer	1.07e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYCS—liver cancer	1.07e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CD—liver cancer	1.07e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—F2—liver cancer	1.06e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.06e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CD—liver cancer	1.06e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PSMD10—liver cancer	1.06e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PSMA4—liver cancer	1.06e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARA—liver cancer	1.06e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ESR1—liver cancer	1.06e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ALB—liver cancer	1.06e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—HRAS—liver cancer	1.05e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GOT1—liver cancer	1.05e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GGT1—liver cancer	1.05e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—liver cancer	1.05e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SERPINE1—liver cancer	1.05e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—F2—liver cancer	1.05e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—liver cancer	1.04e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GOT2—liver cancer	1.03e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—BRAF—liver cancer	1.02e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MTHFR—liver cancer	1.02e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APC—liver cancer	1.02e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CG—liver cancer	1.02e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APC—liver cancer	1e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CG—liver cancer	1e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARA—liver cancer	9.99e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CG—liver cancer	9.88e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—liver cancer	9.84e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—liver cancer	9.8e-06	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2E1—liver cancer	9.69e-06	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CD—liver cancer	9.57e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BRAF—liver cancer	9.56e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—liver cancer	9.53e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARG—liver cancer	9.53e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—liver cancer	9.48e-06	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SERPINE1—liver cancer	9.47e-06	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RAF1—liver cancer	9.46e-06	0.00012	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—liver cancer	9.43e-06	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BRAF—liver cancer	9.41e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	9.38e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—liver cancer	9.37e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CB—liver cancer	9.32e-06	0.000118	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HMOX1—liver cancer	9.3e-06	0.000118	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—liver cancer	9.3e-06	0.000118	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CB—liver cancer	9.24e-06	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MTOR—liver cancer	9.24e-06	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—liver cancer	9.07e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYCS—liver cancer	9.07e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.97e-06	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—liver cancer	8.97e-06	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—liver cancer	8.94e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK14—liver cancer	8.91e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GGT1—liver cancer	8.9e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GOT1—liver cancer	8.9e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—liver cancer	8.85e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SERPINE1—liver cancer	8.84e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—liver cancer	8.82e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—liver cancer	8.8e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—liver cancer	8.75e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—liver cancer	8.75e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—liver cancer	8.74e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—liver cancer	8.71e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SERPINE1—liver cancer	8.7e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—liver cancer	8.68e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—liver cancer	8.67e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—liver cancer	8.67e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—F2—liver cancer	8.63e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—liver cancer	8.61e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—liver cancer	8.61e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—liver cancer	8.58e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—liver cancer	8.57e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—liver cancer	8.55e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RAF1—liver cancer	8.54e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—liver cancer	8.5e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—liver cancer	8.49e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—liver cancer	8.44e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—liver cancer	8.34e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—liver cancer	8.34e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—liver cancer	8.27e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—liver cancer	8.26e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	8.26e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—liver cancer	8.25e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—liver cancer	8.25e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—liver cancer	8.22e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—liver cancer	8.19e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—liver cancer	8.04e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—liver cancer	8.03e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—liver cancer	8e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—liver cancer	7.99e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RAF1—liver cancer	7.98e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—liver cancer	7.97e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—liver cancer	7.96e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—liver cancer	7.91e-06	0.0001	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMOX1—liver cancer	7.88e-06	9.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—liver cancer	7.87e-06	9.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RAF1—liver cancer	7.85e-06	9.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—liver cancer	7.83e-06	9.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK8—liver cancer	7.81e-06	9.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—liver cancer	7.79e-06	9.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—liver cancer	7.79e-06	9.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—liver cancer	7.79e-06	9.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—liver cancer	7.76e-06	9.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—liver cancer	7.74e-06	9.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—liver cancer	7.67e-06	9.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—liver cancer	7.67e-06	9.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	7.67e-06	9.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—liver cancer	7.66e-06	9.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—liver cancer	7.66e-06	9.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—liver cancer	7.62e-06	9.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—liver cancer	7.57e-06	9.59e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—liver cancer	7.52e-06	9.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARA—liver cancer	7.52e-06	9.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—liver cancer	7.47e-06	9.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—liver cancer	7.45e-06	9.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—liver cancer	7.44e-06	9.43e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—liver cancer	7.42e-06	9.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—liver cancer	7.4e-06	9.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—liver cancer	7.34e-06	9.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—liver cancer	7.32e-06	9.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—liver cancer	7.31e-06	9.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	7.26e-06	9.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—liver cancer	7.25e-06	9.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—liver cancer	7.23e-06	9.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—liver cancer	7.22e-06	9.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—liver cancer	7.21e-06	9.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	7.2e-06	9.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	7.19e-06	9.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	7.18e-06	9.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—liver cancer	7.17e-06	9.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—liver cancer	7.16e-06	9.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—liver cancer	7.14e-06	9.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—liver cancer	7.12e-06	9.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	7.12e-06	9.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—liver cancer	7.11e-06	9.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—liver cancer	7.05e-06	8.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK8—liver cancer	7.05e-06	8.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—liver cancer	7.04e-06	8.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—liver cancer	7.03e-06	8.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—liver cancer	7.01e-06	8.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—liver cancer	6.98e-06	8.84e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—liver cancer	6.96e-06	8.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—liver cancer	6.96e-06	8.82e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—liver cancer	6.95e-06	8.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	6.91e-06	8.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—liver cancer	6.87e-06	8.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—liver cancer	6.85e-06	8.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	6.8e-06	8.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—liver cancer	6.77e-06	8.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	6.75e-06	8.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—liver cancer	6.67e-06	8.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	6.64e-06	8.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—liver cancer	6.64e-06	8.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—liver cancer	6.62e-06	8.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK8—liver cancer	6.59e-06	8.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—liver cancer	6.57e-06	8.32e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—liver cancer	6.55e-06	8.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	6.53e-06	8.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—liver cancer	6.51e-06	8.25e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—liver cancer	6.49e-06	8.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK8—liver cancer	6.48e-06	8.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RAF1—liver cancer	6.48e-06	8.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—liver cancer	6.46e-06	8.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—liver cancer	6.45e-06	8.17e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—liver cancer	6.44e-06	8.16e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARA—liver cancer	6.37e-06	8.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	6.33e-06	8.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—liver cancer	6.33e-06	8.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—liver cancer	6.21e-06	7.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—liver cancer	6.13e-06	7.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—liver cancer	6.08e-06	7.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	6.04e-06	7.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—liver cancer	6.02e-06	7.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—liver cancer	5.99e-06	7.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—liver cancer	5.99e-06	7.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—liver cancer	5.98e-06	7.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	5.94e-06	7.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—liver cancer	5.93e-06	7.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	5.88e-06	7.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—liver cancer	5.82e-06	7.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—liver cancer	5.81e-06	7.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—liver cancer	5.78e-06	7.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.72e-06	7.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—liver cancer	5.68e-06	7.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—liver cancer	5.67e-06	7.18e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—liver cancer	5.66e-06	7.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—liver cancer	5.65e-06	7.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	5.63e-06	7.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	5.61e-06	7.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—liver cancer	5.6e-06	7.09e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—liver cancer	5.59e-06	7.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—liver cancer	5.58e-06	7.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—liver cancer	5.54e-06	7.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—liver cancer	5.51e-06	6.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—liver cancer	5.5e-06	6.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—liver cancer	5.49e-06	6.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	5.48e-06	6.95e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—liver cancer	5.45e-06	6.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—liver cancer	5.45e-06	6.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	5.35e-06	6.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	5.34e-06	6.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—liver cancer	5.26e-06	6.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—liver cancer	5.21e-06	6.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—liver cancer	5.17e-06	6.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—liver cancer	5.09e-06	6.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	5.09e-06	6.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—liver cancer	4.99e-06	6.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	4.94e-06	6.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—liver cancer	4.93e-06	6.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—liver cancer	4.92e-06	6.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—liver cancer	4.89e-06	6.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—liver cancer	4.79e-06	6.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	4.75e-06	6.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—liver cancer	4.73e-06	6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—liver cancer	4.7e-06	5.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	4.67e-06	5.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—liver cancer	4.64e-06	5.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—liver cancer	4.61e-06	5.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—liver cancer	4.6e-06	5.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—liver cancer	4.6e-06	5.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—liver cancer	4.54e-06	5.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	4.53e-06	5.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—liver cancer	4.52e-06	5.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—liver cancer	4.5e-06	5.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—liver cancer	4.39e-06	5.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—liver cancer	4.33e-06	5.48e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—liver cancer	4.24e-06	5.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—liver cancer	4.21e-06	5.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—liver cancer	4.2e-06	5.32e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—liver cancer	4.18e-06	5.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—liver cancer	4.15e-06	5.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—liver cancer	4.14e-06	5.25e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—liver cancer	3.99e-06	5.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—liver cancer	3.88e-06	4.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	3.86e-06	4.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—liver cancer	3.82e-06	4.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—liver cancer	3.77e-06	4.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—liver cancer	3.73e-06	4.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—liver cancer	3.57e-06	4.52e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—liver cancer	3.46e-06	4.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—liver cancer	3.42e-06	4.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—liver cancer	3.26e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—liver cancer	3.15e-06	3.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—liver cancer	3.01e-06	3.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—liver cancer	2.55e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—liver cancer	2.46e-06	3.11e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—liver cancer	2.08e-06	2.64e-05	CbGpPWpGaD
